TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $37.67 Average Target Price from Brokerages

TG Therapeutics, Inc. (NASDAQ:TGTX) has earned an average rating of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $40.67.

TGTX has been the subject of a number of research reports. The Goldman Sachs Group increased their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. TD Cowen started coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective for the company. JPMorgan Chase & Co. increased their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. HC Wainwright lifted their price target on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Finally, B. Riley increased their price objective on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the sale, the director now owns 100,195 shares of the company’s stock, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 10.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TGTX. NBC Securities Inc. lifted its position in TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 485 shares during the last quarter. Quarry LP lifted its holdings in shares of TG Therapeutics by 9.1% during the 2nd quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 503 shares during the last quarter. Private Advisor Group LLC grew its position in TG Therapeutics by 3.9% in the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock worth $337,000 after acquiring an additional 542 shares in the last quarter. Blue Trust Inc. increased its stake in TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 849 shares during the last quarter. Finally, KBC Group NV raised its position in TG Therapeutics by 30.5% during the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 1,092 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Trading Down 0.6 %

NASDAQ:TGTX opened at $34.80 on Monday. TG Therapeutics has a 12 month low of $12.37 and a 12 month high of $36.84. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The firm’s 50 day moving average is $26.38 and its 200 day moving average is $22.13. The stock has a market capitalization of $5.42 billion, a PE ratio of -349.97 and a beta of 2.19.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business’s quarterly revenue was down 49.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.73 earnings per share. Sell-side analysts expect that TG Therapeutics will post 0.17 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.